InDevR Raises $7 million in Series A Financing with Adjuvant Capital Boulder, CO, 10 September 2019 – InDevR, Inc., a biotechnology company focused on developing and commercializing novel analytical technologies ...
Read More

Clinical validation of the FluChip-8G Influenza A+B Assay for influenza type and subtype identification published in Journal of Clinical Virology Go to Abstract  ...
Read More

Analytical Evaluation of the Microarray-Based FluChip-8G Influenza A+B Assay published in Journal of Virological Methods Go to Abstract  ...
Read More

ASM Microbe 2019 InDevR will be present at the ASM conference in San Francisco in June. Rose Nash will be offering a presentation, "Assessment of the Correlation between Alternative Influenza ...
Read More

510(k) Market Clearance for FluChip-8G Influenza A+B Assay InDevR receives 510(k) market clearance for the first influenza diagnostic assay capable of distinguishing between seasonal and non-seasonal influenza A subtypes ...
Read More

InDevR Chosen for NIH’s Innovation Zone at BIO International Convention One of select group of NIH SBIR awardees to be featured at BIO   BOULDER COLORADO (4/9/19) — ...
Read More